Journal: Neuropharmacology

Article Title: The H3 Antagonist, Ciproxifan, Alleviates the Memory Impairment but Enhances the Motor Effects of MK-801 (Dizocilpine) in Rats.

doi: 10.1016/j.neuropharm.2010.07.004

Figure Lengend Snippet: Effects of ciproxifan and MK-801 on PPI after presentation of a 5 dB (left graph), 10 dB (middle graph), and 15 dB prepulse auditory stimulus (right graph). Symbols indicate significant differences within each of the three ciproxifan pretreatment groups at each intensity – an asterisk (*) indicates a significant difference from saline treatment and a cross (+) indicates a significant difference from saline and MK-801 (0.05 mg/kg) treatments. Group differences refer to outcomes of post-hoc comparisons that were significant at p ≤ .05 (Fishers PLSD) and are indicated by connecting lines. Data represent average % of PPI (see text for further definition) ± s.e.m during prepulse inhibition trials. n = 12 rats per group.

Article Snippet: Ciproxifan (free base) was kindly provided by the National Institute of Mental Health’s Chemical Synthesis and Drug Supply program, and (+)-MK-801 hydrogen maleate was purchased from Sigma (St. Louis, MO).

Techniques: Inhibition

Journal: Neuropharmacology

Article Title: The H3 Antagonist, Ciproxifan, Alleviates the Memory Impairment but Enhances the Motor Effects of MK-801 (Dizocilpine) in Rats.

doi: 10.1016/j.neuropharm.2010.07.004

Figure Lengend Snippet: Effects of ciproxifan pretreatment on the number of fine movements seen after treatment with: A.) saline treatment, B.) MK-801 0.05 mg/kg, C.) MK-801 0.1 mg/kg, and D.) MK-801 0.3 mg/kg. A plus sign (+) indicates a significant difference between the saline and Cip 1.0 dose group. A number sign (#) indicates a significant difference between the saline and Cip 3.0 dose group. Group differences refer to outcomes of post-hoc comparisons that were significant at p ≤ .05 (Fishers PLSD) and are indicated by connecting lines . Data represent the mean number of photobeam breaks every five minutes ± s.e.m. There were 12 animals in each group although a separate cohort of 12 rats was used to generate the data depicted in d.

Article Snippet: Ciproxifan (free base) was kindly provided by the National Institute of Mental Health’s Chemical Synthesis and Drug Supply program, and (+)-MK-801 hydrogen maleate was purchased from Sigma (St. Louis, MO).

Techniques:

Journal: Neuropharmacology

Article Title: The H3 Antagonist, Ciproxifan, Alleviates the Memory Impairment but Enhances the Motor Effects of MK-801 (Dizocilpine) in Rats.

doi: 10.1016/j.neuropharm.2010.07.004

Figure Lengend Snippet: Effects of ciproxifan pretreatment on measures of ataxia recorded after treatment with MK-801. A.) Each dose of MK-801 decreased the time spent on the platform and ciproxifan (3.0 mg/kg) enhanced the effect of the 0.1 mg/kg dose as indicated by the asterisk. B). The 0.3 mg/kg dose of MK-801 significantly increased the latency for walking initiation. C.) Each dose of MK-801 increased the righting reflex and ciproxifan (3.0 mg/kg) enhanced the effect of the 0.3 mg/kg dose as indicated by the asterisk. Group differences refer to outcomes of post-hoc comparisons that were significant at p ≤ .05 (Fishers PLSD) and are indicated by connecting lines. Data represent mean seconds ± s.e.m. n = 12 rats per group.

Article Snippet: Ciproxifan (free base) was kindly provided by the National Institute of Mental Health’s Chemical Synthesis and Drug Supply program, and (+)-MK-801 hydrogen maleate was purchased from Sigma (St. Louis, MO).

Techniques:

Journal: Neuropharmacology

Article Title: The H3 Antagonist, Ciproxifan, Alleviates the Memory Impairment but Enhances the Motor Effects of MK-801 (Dizocilpine) in Rats.

doi: 10.1016/j.neuropharm.2010.07.004

Figure Lengend Snippet: Effects of ciproxifan and MK-801 on startle responses to the auditory stimulus and activity during no startle trials during each block of sensorimotor testing. A.) Each dose of MK-801 significantly enhanced auditory startle responses regardless of ciproxifan pretreatment as indicated by asterisk. B.) The high dose of MK-801 significantly increased activity during the no startle trials relative to saline treatment as indicated by the asterisk. After treatment with this dose, activity was greater during test block 2 than test block 1 as indicated by a + sign. Group differences refer to outcomes of post-hoc comparisons that were significant at p ≤ .05 (Fishers PLSD) and are indicated by connecting lines. Data represent average force (expressed in newtons) ± s.e.m during startle and no startle trials. n = 12 rats per group.

Article Snippet: Ciproxifan (free base) was kindly provided by the National Institute of Mental Health’s Chemical Synthesis and Drug Supply program, and (+)-MK-801 hydrogen maleate was purchased from Sigma (St. Louis, MO).

Techniques: Activity Assay, Blocking Assay

Journal: Neuropharmacology

Article Title: The H3 Antagonist, Ciproxifan, Alleviates the Memory Impairment but Enhances the Motor Effects of MK-801 (Dizocilpine) in Rats.

doi: 10.1016/j.neuropharm.2010.07.004

Figure Lengend Snippet: Effects of ciproxifan and MK-801 on delayed spatial alternation at a 10 second (left graph) or 40 second delay (right graph). Pretreatment with saline and treatment with 0.1 mg/kg of MK-801 caused a significant performance deficit at the 40 second delay relative to the effect of saline pretreatment and treatment as indicated by the asterisk. Animals treated with 0.1 mg/kg of MK-801 performed significantly better at the 40 s delay when they received pretreatment with the 3.0 mg/kg dose of ciproxifan as opposed to saline pretreatment, as indicated by the cross. Group differences refer to outcomes of post-hoc comparisons that were significant at p ≤ .05 (Fishers PLSD) and are indicated by connecting lines. Data represent average number of correct choices ± s.e.m. n = 11 rats per group.

Article Snippet: Ciproxifan (free base) was kindly provided by the National Institute of Mental Health’s Chemical Synthesis and Drug Supply program, and (+)-MK-801 hydrogen maleate was purchased from Sigma (St. Louis, MO).

Techniques:

Journal: Neuropharmacology

Article Title: The H3 Antagonist, Ciproxifan, Alleviates the Memory Impairment but Enhances the Motor Effects of MK-801 (Dizocilpine) in Rats.

doi: 10.1016/j.neuropharm.2010.07.004

Figure Lengend Snippet: Effects of ciproxifan pretreatment on locomotor activity after A.) saline treatment, B.) MK-801 0.05 mg/kg, C.) MK-801 0.1 mg/kg, and D.) MK-801 0.3 mg/kg. An asterisk (*) indicates a significant difference between rats pretreated with either dose of ciproxifan and those pretreated with saline. A plus sign (+) indicates a significant difference between the saline and Cip 1.0 dose group. A number sign (#) indicates a significant difference between the saline and Cip 3.0 dose group. A § indicates a significant difference between the Cip 3.0 dose groups and the two other groups. Group differences refer to outcomes of post-hoc comparisons that were significant at p ≤ .05 (Fishers PLSD) and are indicated by connecting lines . Data represent the mean number of photobeam breaks every five minutes ± s.e.m. There were 12 animals in each group although a separate cohort of 12 rats was used to generate the data depicted in d.

Article Snippet: Ciproxifan (free base) was kindly provided by the National Institute of Mental Health’s Chemical Synthesis and Drug Supply program, and (+)-MK-801 hydrogen maleate was purchased from Sigma (St. Louis, MO).

Techniques: Activity Assay

Journal: BMC Neuroscience

Article Title: Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT1A agonist in rat models of ischaemic stroke

doi: 10.1186/1471-2202-10-82

Figure Lengend Snippet: Neuroprotective efficacy of the 5HT1A agonist DU123015 and positive control MK-801 in the 60 minutes distal MCAo model . (A) The body weights of animals treated with DU123015 and glucosaline-treated controls. No significant differences between groups were observed. (B) The body weights for MK-801 and saline-treated controls. No significant differences between groups were observed. Neither DU123015 (C), nor MK-801 (D), significantly improve neurological functions, although on day 2 MK-801 almost significantly improved function (P = 0.056). (E) Oedema corrected MRI lesion volumes did not differ for DU123015-treated animals and glucosaline controls. (F) MK-801-treated animals exhibited a significant reduction in lesion volume at both time-points. (**) P

Article Snippet: Treating animals with MK-801 or DU123015 therefore did not significantly accelerate recovery of pre-operative weights.

Techniques: Positive Control, Magnetic Resonance Imaging

Journal: BMC Neuroscience

Article Title: Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT1A agonist in rat models of ischaemic stroke

doi: 10.1186/1471-2202-10-82

Figure Lengend Snippet: Neuroprotective efficacy of 5HT1A agonist DU123015 and positive control MK-801 in the 120 minutes distal MCAo model . The body weights (absolute weight in grams ± SEM) did not differ significantly for DU123015- (A) or MK-801-treated subjects (B). (C) No significant differences on neurological deficit were found for DU123015- (D) or MK-801-treated animals (E). No significant differences between groups were observed for oedema corrected MRI lesion volumes for DU123015-treated animals and glucosaline control treated animals (F). Also, no significant reduction in lesions was detected using the positive control compound MK-801.

Article Snippet: Treating animals with MK-801 or DU123015 therefore did not significantly accelerate recovery of pre-operative weights.

Techniques: Positive Control, Magnetic Resonance Imaging

Journal: BMC Neuroscience

Article Title: Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT1A agonist in rat models of ischaemic stroke

doi: 10.1186/1471-2202-10-82

Figure Lengend Snippet: Neuroprotective efficacy of 5HT1A agonist DU123015 and positive control MK-801 in the 90 minutes Intra-Luminal Tread (ILT) model of MCAo . The body weights of animals treated with DU123015 (A) and MK-801 (B). (C) No significant differences were observed on neurological functions in animals treated with DU123015 (D) A Kruskall-Wallis non-parametric test indicated that MK-801 improved neurological functions impaired by stroke. (E) No significant differences were observed on oedema corrected MRI lesion volume for DU123015-treated animals. (F) In contrast, MK-801 significantly reduced lesion volume at all time points (*) P

Article Snippet: Treating animals with MK-801 or DU123015 therefore did not significantly accelerate recovery of pre-operative weights.

Techniques: Positive Control, Magnetic Resonance Imaging

Journal: BMC Neuroscience

Article Title: Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT1A agonist in rat models of ischaemic stroke

doi: 10.1186/1471-2202-10-82

Figure Lengend Snippet: Bilateral Asymmetry Test (BAT) for 90 minutes intra-luminal thread model of MCAo . DU123015 did not improve the total time taken to remove sticky tape from forepaws (A), whereas MK-801 did significantly improved outcome (B) Difference between removal of the sticky tape from the right and left forepaws (L-R) did not improve with DU123015 treatment (C), whereas MK-801 did (D).

Article Snippet: Treating animals with MK-801 or DU123015 therefore did not significantly accelerate recovery of pre-operative weights.

Techniques: